Amanta Healthcare Limited has informed the Exchange about Transcript
AMANTA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Amanta Healthcare reported FY26 revenue of INR288 crores (up 5% YoY) with EBITDA of INR63 crores maintaining 22% margin. PAT grew 42% YoY to INR15 crores, supported by lower finance costs and operating leverage. The company is expanding SteriPort capacity from 6.6 crore to 12 crore bottles per year, with new line expected operational by June 20, 2026. Management guided EBITDA margin of 25%+ going forward as the new capacity ramps up. Polymer prices have risen 60-70%, but the company has implemented 5-6% price increases to protect margins. Debt-to-equity improved from 3x to 1x over three years, with 90% of borrowing now at single-digit rates. The company has 20 products in pipeline across inhalation and ophthalmic segments. Export contribution increased from 32% to 39% of revenue.
The capacity expansion in high-margin SteriPort products combined with lower debt costs positions the company for significant profitability improvement in FY27, with management guiding 25%+ EBITDA margins and disproportionate PAT growth. The stock could see re-rating as the expansion delivers revenues from Q2 FY27 onward.